Can perindopril (Angiotensin-Converting Enzyme inhibitor) cause headaches?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Perindopril and Headache

Yes, perindopril can cause headaches, with headache reported in 23.8% of patients in clinical trials, though this rate was not significantly higher than placebo. 1

Evidence from FDA Drug Label

The FDA-approved labeling for perindopril provides clear data on headache incidence:

  • Headache occurred in 23.8% of perindopril-treated patients in U.S. placebo-controlled trials, making it one of the most commonly reported complaints 1
  • Headache was among the most common causes of premature discontinuation (along with cough, asthenia, and dizziness), though the overall discontinuation rate was similar to placebo (6.5% vs 6.7%) 1
  • Importantly, headache was not reported more frequently with perindopril than with placebo by at least 1%, which is why it doesn't appear in the table of adverse events that were definitively more common than placebo 1

Clinical Context and Interpretation

The relationship between perindopril and headache requires nuanced interpretation:

  • The 23.8% incidence likely reflects background headache prevalence in the hypertensive population rather than a drug-induced effect, since the rate was not significantly elevated compared to placebo 1
  • In long-term European studies of 856 patients, headache was reported in only 5.6% of patients, with an overall side effect withdrawal rate of just 6.8% 2
  • Perindopril is generally well-tolerated with a favorable safety profile across diverse patient populations including elderly and those with comorbidities 3, 4

Practical Management Approach

When a patient on perindopril reports headaches:

  • First, determine if the headache predates perindopril initiation or represents worsening of pre-existing headaches, as most cases are not drug-related 1
  • Assess for dose-related effects: Unlike dizziness (which clearly increased with perindopril dose), headache did not show dose-dependency in clinical trials 1
  • Consider alternative ACE inhibitor-related causes: Evaluate for hypotension, which was a common reason for discontinuation in the EUROPA trial 1
  • Rule out medication overuse headache if the patient is taking frequent analgesics, as this is a critical consideration in any patient with chronic headaches 5

Key Clinical Caveat

Do not reflexively discontinue perindopril for headache alone, as the evidence suggests headache is not a true drug-induced adverse effect in most cases. The cardiovascular and renal benefits of perindopril (including reduced proteinuria and improved arterial compliance) typically outweigh non-specific headache complaints that occur at similar rates as placebo. 3, 4

References

Research

Safety profile of perindopril.

The American journal of cardiology, 2001

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.